AbbVie Shares Dip Despite MAVYRET's Expanded FDA Approval Ranking 88th in Market Activity

AbbVie (ABBV) shares fell 0.70% on June 13, 2025, with a trading volume of $9.51 billion, ranking 88th in the day's market activity.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for AbbVie's MAVYRET, an oral pangenotypic direct-acting antiviral (DAA) therapy. This approval now includes the treatment of adults and pediatric patients aged three and older with acute or chronic hepatitis C virus (HCV) infection, with or without compensated cirrhosis. MAVYRET is the first and only DAA therapy approved to treat patients with acute HCV in just eight weeks, achieving a 96% cure rate.

HCV is a highly infectious blood-borne disease that affects the liver. Early treatment with safe and effective therapies can cure virtually all patients with hepatitis C, preventing the progression to chronic disease, cirrhosis, or liver cancer. The public health community aims to eliminate HCV by 2030, but nearly 80% of high-income countries, including the U.S., are not on track to achieve this goal until after 2050.

Roopal Thakkar, M.D., executive vice president of research and development and chief scientific officer at AbbVie, highlighted the significance of this approval. 'Mavyret has treated more than one million patients with HCV, but we recognize that a significant need remains for patients with acute infection,' she said. 'The label expansion for MAVYRET, coupled with the implementation of test and treat models of care, serve as tools to support the public health community in treating more patients and bringing us closer to achieving the global 2030 elimination goal.'